AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$PHVS

Abele Stefan Andreas sold $1.8M of PHVS

Abele Stefan Andreas (Chief Technical Ops Officer) sold 46,400 shares of Pharvaris N.V. (PHVS) at an average of $38.17 ($38.14–$39.24, $1.77M total) across 2 trades on 2026-09-15.

Original reporting
SEC EDGAR · Abele Stefan Andreas
Published Sep 17, 2026, 5:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 5:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as a negative cue by the market.

02

Market read

First‑report insider sale of a C‑level executive; modest materiality for a small‑cap biotech.

03

What to watch

No 10b5‑1 plan; the timing may be unrelated to company fundamentals.

Relevance 6/10Novelty 6/10Timing: filing disclosed on 2026-09-17

Background

SEC Form 4 filing discloses insider transactions; PHVS is a biotech listed on Nasdaq.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Chief Technical Ops Officer sold 46,400 shares for $1.77M, reducing his stake to 39,068 shares.

Expected impact

Modest downside pressure, likely 1‑2% dip over the next few days.

Evidence & confidence

C‑level insider sales are watched closely; the $1.8M sale is material for a small‑cap biotech and could trigger sell‑offs.

Market effects

Sector

May raise concerns for other biotech firms with recent insider sales.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Company
    Pharvaris N.V.

    Biotech firm developing therapies for rare diseases.

  • Individual
    Abele Stefan Andreas

    Chief Technical Ops Officer of Pharvaris.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min